This study is for verification of predictive biomarkers for pancreatic cancer treatment using multi-center liquid biopsy.

Clinical applicability of KRAS mutations using circulating-tumor DNA in pancreatic cancer patients.

• Quantification and monitoring of KRAS mutations Using droplet digital PCR in ctDNA extracted from collected patient samples.
• Correlation analysis of KRAS mutation results with clinical data.

Discovery of biomarkers for predicting pancreatic cancer prognosis through ctDNA panel.

• Gene panel composition for pancreatic cancer therapeutic target determination and monitoring.
• A panel was performed using gDNA and ctDNA of tumor tissue collected from pancreatic cancer patients.
• Comparative analysis of panel results and quantitative KRAS mutations and evaluation of clinical applicability.

Inclusion Criteria:

• Patients with pathologically confirmed pancreatic adenocarcinoma.

Exclusion Criteria:

• Patients disagree with the study.

Inpatient or outpatient